DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Virtual Event

2021年6月08日 (火) 午後 7:00 - 2021年6月11日 (金) 午前 12:00

(Central Europe Standard Time)

4051 Basel, Switzerland

Future of Evidence and Smart Health Conference

Leveraging RWE to advance healthcare decision-making.

Session 4: Application of AI & ML in Drug Development and Approval

Session Chair(s)

Niels  Leander, PHD

Niels Leander, PHD

Partner - Life Sciences

Eraneos, Denmark

This session will bring together leading technology providers to combine a focus on the drug development approval process with the data stemming from patients’ use of the medicine approved. From Regulatory Affairs, the perspective is on streamlining the approval process by reference to the right data and on demonstrating and maintaining a safety profile, supported by the patients’ observations. However, the role of the patient is rapidly changing due to technology, and this session will demonstrate and discuss the technologies that will potentially transform the approval process and the safety monitoring of the drugs.

Speaker(s)

Niels  Leander, PHD

Intro - Application of AI & ML in Drug Development and Approval

Niels Leander, PHD

Eraneos, Denmark

Partner - Life Sciences

Susant  Mallick, MBA

Embracing Real World Evidence (RWE) & Robotic Process Automation to transform Regulatory Affairs Submission Process

Susant Mallick, MBA

Cloudhub BV, Netherlands

Founder and CEO, Life Sciences Practice Leader

Niels  Gronning, MSC

AI and ML in a Drug Development Perspective

Niels Gronning, MSC

Microsoft, Denmark

Senior Specialist

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。